TRELEGY Ellipta was developed in collaboration with INNOVIVA Inc.
TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA4
Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 firstname.lastname@example.org. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Registered in Ireland: GlaxoSmithKline (Ireland) Limited, a private company limited by shares, and a member of the GlaxoSmithKline group of companies. Registered in Ireland with Company Number 15513. Registered office: 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.